AUROPHARMA · NSE
Aurobindo Pharma Limited
₹1,799
-0.37% (-₹6.7)
Prev. close
₹1,805.7
Volume
8,11,247
Delivery %
61.6%
As of
20 Nov 2026
Price history
Analyst sentiment
Analysts lean bullish
5 analyst stances · last 90 days · one per analyst
Trackable
5 · 5 bull / 0 neutral / 0 bear
Long-Horizon
none in range
Commentary
none in range
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Bullish on Aurobindo Pharma, recommending a buy at CMP ₹1,695 with a target of ₹1,800 and a stop loss at ₹1,640. The sto…” | Rupak DeLKP Securities | Aurobindo Pharma | MISS | |
| “Bullish on Aurobindo Pharma with a target price of ₹1,840. Several growth triggers are identified, including Eugia, PenG…” | Angel One AnalysisAngel One | Aurobindo Pharma | HIT | |
| “Bullish on Aurobindo Pharma, retaining a 'Buy' rating with a target price of ₹1,840, implying a 10% upside from current …” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Aurobindo Pharma | HIT | |
| “Bullish on Aurobindo Pharma Futures, recommending a buy in the ₹1,650-1,700 range with targets at ₹1,800-1,870 and a sto…” | Jay ThakkarICICI Securities | Aurobindo Pharma | MISS | |
| “Bullish on Aurobindo Pharma, recommending a buy with a target price of ₹1,820 and a stop loss of ₹1,665. The stock is in…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Aurobindo Pharma | MISS | |
| “Recommends buying Aurobindo Pharma Futures in the ₹1,650-1,660 range, targeting ₹1,740-1,780, with a stop loss below ₹1,…” | Jay ThakkarICICI Securities | Aurobindo Pharma | MISS | |
| “CA Rudramurthy BV is bullish on Aurobindo Pharma, identifying it as a buying opportunity on dips due to overall market w…” | CA Rudramurthy BVVachana Investments | Aurobindo Pharma | MISS | |
| “Bearish on Aurobindo Pharma (AUROPHARMA), recommending a sell below ₹1165 with a target of ₹1140 and a stop loss at ₹118…” | Raja VenkatramanNeoTrader | Aurobindo Pharma | NOT TRIGGERED | |
| “Recommends buying Aurobindo Pharma for the next one to two weeks with a target price of ₹1,320 and a stop loss of ₹1,168…” | Ajit MishraReligare Broking | Aurobindo Pharma Limited | MISS | |
| “Bullish on Aurobindo Pharma for the near term, recommending a buy at ₹1,149.10 with targets of ₹1,250 and ₹1,280, and a …” | Vishnu Kant UpadhyayMaster Capital Services | Aurobindo Pharma | MISS | |
| “Bullish on Aurobindo Pharma for the short term (1-2 weeks), targeting ₹1,300 with a stop loss at ₹1,090. The stock shows…” | Ajit MishraReligare Broking | Aurobindo Pharma | MISS | |
| “Bullish on Aurobindo Pharma for the next one to two weeks, suggesting long positions in the ₹1,120–₹1,140 zone, targetin…” | Jigar S. PatelAnand Rathi Share and Stock Brokers | Aurobindo Pharma | MISS | |
| “Recommends buying Aurobindo Pharma at ₹1,144, setting a stop-loss at ₹1,104, with a target price of ₹1,224. This call is…” | Sumeet BagadiaChoice Equity Broking | Aurobindo Pharma Ltd | HIT | |
| “Bullish on Aurobindo Pharma for the next one to two weeks, with a target price of ₹1,250 and a stop loss at ₹1,060. The …” | Ajit MishraReligare Broking | Aurobindo Pharma Ltd | MISS | |
| “Recommends buying Aurobindo Pharma shares for a target price of ₹1,170, with a stop loss at ₹1,075. The stock has broken…” | Chandan TapariaMotilal Oswal Financial Services Ltd | Aurobindo Pharma | MISS | |
| “Bullish on Aurobindo Pharma Ltd., recommending a buy at ₹1050 with a stop loss at ₹1020 for a target price of ₹1090. The…” | Ganesh DongreAnand Rathi | Aurobindo Pharma Ltd. | HIT | |
| “Recommends buying Aurobindo Pharma at ₹1,042, targeting ₹1,100 with a stop loss at ₹1,010 for the week ahead, based on t…” | Ganesh DongreAnand Rathi | Aurobindo Pharma | HIT | |
| “Prabhudas Lilladher recommends buying Aurobindo Pharma with a target price of ₹1300. The call implies a bullish outlook …” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Aurobindo Pharma | HIT | |
| “Bullish on Aurobindo Pharma, recommending a buy around ₹1158 with a stop-loss at ₹1117 for a target of ₹1240. The stock …” | Sumeet BagadiaChoice Equity Broking | Aurobindo Pharma Ltd. | MISS | |
| “Maintains a 'buy' rating on Aurobindo Pharma, targeting ₹1,500, driven by strong performance in the pharmaceutical secto…” | Axis Securities AnalysisAxis Securities | Aurobindo Pharma Ltd | HIT | |
| “Prabhudas Lilladher recommends buying Aurobindo Pharma with a target price of ₹1440. The call implies a bullish outlook …” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Aurobindo Pharma | HIT | |
| “Recommends buying Aurobindo Pharma above ₹1,245, with a stop loss at ₹1,198 and targets of ₹1,315 and ₹1,350. The stock …” | Sachin Gupta5paisa | Aurobindo Pharma Ltd | PENDING | |
| “Recommends buying Aurobindo Pharma at ₹1220 with a stop loss at ₹1170 and a target price of ₹1300. This call is for Mond…” | Ganesh DongreAnand Rathi | Aurobindo Pharma | MISS | |
| “Recommends buying Aurobindo Pharma Ltd (AUROPHARMA) in the range of ₹1,140-1,160, setting a target price of ₹1,200 with …” | Ganesh DongreAnand Rathi | Aurobindo Pharma Ltd | MISS | |
| “Recommends buying Aurobindo Pharma Ltd at ₹1,136, targeting ₹1,175 with a stop loss at ₹1,105. The stock is in an overso…” | Ganesh DongreAnand Rathi | Aurobindo Pharma Ltd | HIT | |
| “Elara has reiterated its 'Buy' rating on Aurobindo Pharma with a target price of Rs 1,568, implying a 48% upside. The st…” | Elara Capital AnalysisElara Capital | Aurobindo Pharma Ltd | MISS | |
| “Bullish on Aurobindo Pharma Ltd, recommending a buy at ₹1,135 with a stop loss at ₹1,110 for a target price of ₹1,170. A…” | Ganesh DongreAnand Rathi | Aurobindo Pharma Ltd | MISS | |
| “Bullish on Aurobindo Pharma with a 'Buy' recommendation, setting a target price of ₹1510. The call is based on the compa…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Aurobindo Pharma Ltd | MISS | |
| “Maintained a 'Sell' rating on Aurobindo Pharma with a target price of Rs 1,333. The brokerage highlighted a strong ramp-…” | UBS AnalysisUBS | Aurobindo Pharma Ltd | PENDING | |
| “Maintained a 'Buy' rating on Aurobindo Pharma with a target price of Rs 1,912. The brokerage noted higher US sales over …” | Investec AnalysisInvestec | Aurobindo Pharma Ltd | MISS | |
| “Upgraded Aurobindo Pharma to 'outperform' despite cutting its target price to ₹1400 (from ₹1540), still suggesting a 14%…” | CLSA AnalysisCLSA | Aurobindo Pharma | MISS | |
| “JM Financial recommends buying Aurobindo Pharma with a target price of Rs 1755, up from the current Rs 1173.7. The broke…” | JM Financial AnalysisJM Financial Institutional Securities | Aurobindo Pharma | MISS | |
| “Axis Securities has an 'Overweight' call on Aurobindo Pharma, setting a target price of Rs 1,500 against the current mar…” | Axis Securities AnalysisAxis Securities | Aurobindo Pharma Ltd | MISS | |
| “Short-term traders are advised to buy Aurobindo Pharma stock, targeting ₹1,500 in the medium-term. The stock has rebound…” | ETMarkets AnalysisETMarkets.com | Aurobindo Pharma Ltd | MISS | |
| “Bullish on Aurobindo Pharma Ltd, recommending a buy at ₹1348 with targets of ₹1405-1426 and a stop loss at ₹1320. The st…” | Ankush BajajIndependent | Aurobindo Pharma Limited | PENDING | |
| “Recommends buying Aurobindo Pharma with a target price of ₹1591. The call implies a bullish outlook on the stock.” | Deven Choksey Research AnalysisDeven Choksey Research | Aurobindo Pharma | PENDING | |
| “Prabhudas Lilladher recommends accumulating Aurobindo Pharma, setting a target price of ₹1475. The call implies a bullis…” | Prabhudas Lilladher AnalysisPrabhudas Lilladher | Aurobindo Pharma | PENDING | |
| “Bearish on Aurobindo Pharma October Futures, recommending a sell with a stop loss at ₹1,525 and a target price of ₹1,382…” | Sagar DoshiNuvama Professional Clients Group | Aurobindo Pharma | HIT | |
| “Recommends buying Aurobindo Pharma at ₹1465 for a target price of ₹1535, with a stop loss at ₹1410.” | Ganesh DongreAnand Rathi | Aurobindo Pharma | MISS | |
| “Recommends buying Aurobindo Pharma with a target price of ₹1,730, citing several growth levers expected to drive the com…” | Axis Securities AnalysisAxis Securities | Aurobindo Pharma Ltd | PENDING | |
| “Recommends shorting Aurobindo Pharma October Futures in the ₹1,480-1,490 range for a potential target around ₹1,390, wit…” | Ruchit Jain5paisa | Aurobindo Pharma | MISS |
Market commentary · 3 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “Dipan Mehta is positive on Aurobindo Pharma, viewing recent Form 483 observations as not a major concern due to diversif…” | Dipan MehtaElixir Equities | Aurobindo Pharma Limited | — | |
| “Nuvama recommends Aurobindo Pharma, projecting a 34% upside over the next 12 months. The brokerage highlights strong gro…” | Nuvama AnalysisNuvama Alternative & Quantitative Research | Aurobindo Pharma Limited | — | |
| “Downgraded Aurobindo Pharma to 'Add' from 'Buy' with a revised target price of ₹1,330 (previously ₹1,445), based on 16x …” | ICICI Securities AnalysisICICI Securities | Aurobindo Pharma Ltd | — |
Fundamentals
About Aurobindo Pharma Limited
Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeutic areas. It also provides ointments, creams, gels, powders, transdermal, and lotions; antiretroviral drugs for PLHIV & CLHIV; and injectable products, including Penems, Penicillin, Cephalosporin, ophthalmic, inhalation, oncology, and hormone products. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
Details
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Dr. Makkapati Satakarni B.E., M.B.A., Ph.D.
Headquarters
Hyderabad
Employees
29,209
Website
aurobindo.comExchange
View on NSE ↗Key stats
Market cap
₹98,101.93 Cr
P/E ratio (TTM)
26.6
Dividend yield
0.00%
EPS (TTM)
₹64.00
Beta (1Y · daily vs NIFTY 50)
0.39
Beta (5Y · monthly vs NIFTY 50)
0.89
Shares float
27.61 Cr
EPS · quarter ended Jun 2026
₹17.86
Financial Performance
01 · Financials
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based
05 · Capital Structure & Asset Utilization
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
07 · Debt Level & Coverage
Total assets for FY23, FY24, FY25 and FY26: the figure the company printed, which its own totals confirm and the series' figure did not.
08 · Profit & Loss — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹25,155.47 Cr | ₹23,775.84 Cr | ₹25,145.97 Cr | ₹29,559.25 Cr | ₹32,345.58 Cr | ₹34,145.17 Cr | |
| ₹20,571.10 Cr | ₹20,243.88 Cr | ₹22,521.80 Cr | ₹24,970.24 Cr | ₹27,247.60 Cr | ₹28,969.51 Cr | |
PROFIT BEFORE SHARE OF (LOSS)/PROFIT OF JOINT VENTURES | ₹4,584.37 Cr | ₹3,531.96 Cr | ₹2,624.17 Cr | ₹4,589.01 Cr | ₹5,097.98 Cr | ₹5,175.66 Cr |
Share of Profit/ (loss) of associates and joint ventures (net of tax) | ₹-55.36 Cr | ₹-31.25 Cr | ₹-11.67 Cr | ₹-17.16 Cr | ₹-31.69 Cr | ₹1.52 Cr |
PROFIT BEFORE EXCEPTIONAL ITEMS AND TAX (III+IV) | ₹4,529.01 Cr | ₹3,500.71 Cr | ₹2,612.50 Cr | ₹4,571.85 Cr | ₹5,066.29 Cr | ₹5,177.18 Cr |
Exceptional items | ₹-2,814.58 Cr | ₹127.97 Cr | — | ₹191.86 Cr | — | ₹65.33 Cr |
PROFIT BEFORETAX (V-VI) | ₹7,343.59 Cr | ₹3,372.74 Cr | ₹2,612.50 Cr | ₹4,379.99 Cr | ₹5,066.29 Cr | ₹5,111.85 Cr |
| ₹2,009.77 Cr | ₹725.63 Cr | ₹684.85 Cr | ₹1,211.02 Cr | — | — | |
TOTALTAX EXPENSE (VIII) | — | — | — | — | ₹1,582.72 Cr | ₹1,608.88 Cr |
| ₹5,338.56 Cr | ₹2,908.76 Cr | ₹2,663.23 Cr | ₹3,268.13 Cr | ₹3,787.19 Cr | ₹5,468.17 Cr | |
PROFIT FOR THE YEAR (VII-VIII) | ₹5,333.82 Cr | ₹2,647.11 Cr | ₹1,927.65 Cr | ₹3,168.97 Cr | ₹3,483.57 Cr | ₹3,502.97 Cr |
| ₹4.74 Cr | ₹261.65 Cr | ₹735.58 Cr | ₹99.16 Cr | ₹303.62 Cr | ₹1,965.20 Cr | |
Owners of the Parent Company | ₹5,339.58 Cr | ₹2,909.80 Cr | ₹2,663.08 Cr | ₹3,272.13 Cr | ₹3,789.51 Cr | ₹5,469.94 Cr |
Non-controlling interest | ₹-1.02 Cr | ₹-1.04 Cr | ₹15.00 L | ₹-4.00 Cr | ₹-2.32 Cr | ₹-1.77 Cr |
Owners of the Parent Company | ₹5,334.84 Cr | ₹2,648.15 Cr | ₹1,927.50 Cr | ₹3,172.97 Cr | ₹3,485.88 Cr | ₹3,504.75 Cr |
Non-controlling interest | ₹-1.02 Cr | ₹-1.04 Cr | ₹15.00 L | ₹-4.00 Cr | ₹-2.31 Cr | ₹-1.78 Cr |
Owners of the Parent Company | ₹4.74 Cr | ₹261.65 Cr | ₹735.58 Cr | ₹99.16 Cr | ₹303.63 Cr | ₹1,965.19 Cr |
Non-controlling interest | — | — | — | — | ₹-1.00 L | ₹1.00 L |
(ii) Diluted (in ₹) | 91.05 | 45.19 | — | — | — | — |
Nominal value per equity share | 1.00 | 1.00 | — | — | — | — |
Basic and diluted (in) | 91.05 | 45.19 | 32.90 | 54.16 | 59.81 | 60.34 |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
09 · Balance Sheet — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹33,853.99 Cr | ₹33,921.72 Cr | ₹39,889.99 Cr | ₹45,071.51 Cr | ₹49,784.97 Cr | ₹58,502.15 Cr | |
(i) Borrowings | ₹168.49 Cr | — | — | — | — | — |
(ii) Lease liabilities | ₹266.19 Cr | — | — | — | — | — |
(b) Provisions | ₹157.11 Cr | — | — | — | — | — |
(i) Borrowings | ₹4,803.78 Cr | — | — | — | — | — |
(iii) Lease liabilities | ₹100.62 Cr | — | — | — | — | — |
(iv) Other financial liabilities | ₹2,027.50 Cr | — | — | — | — | — |
(c) Provisions | ₹171.93 Cr | — | — | — | — | — |
| ₹21,928.99 Cr | — | — | — | — | — | |
| ₹21,928.99 Cr | ₹24,574.05 Cr | ₹26,851.85 Cr | ₹29,850.80 Cr | ₹32,646.93 Cr | ₹37,882.81 Cr | |
| ₹1,259.95 Cr | — | — | — | — | — | |
Total non-current liabilities | ₹1,259.95 Cr | ₹1,191.69 Cr | ₹1,544.36 Cr | ₹3,021.58 Cr | ₹2,455.70 Cr | ₹2,580.33 Cr |
| ₹10,665.05 Cr | — | — | — | — | — | |
| ₹33,853.99 Cr | — | — | — | — | — | |
TOTAL EQUITY AND LIABILITIES | ₹33,853.99 Cr | ₹33,921.72 Cr | ₹39,889.99 Cr | ₹45,071.51 Cr | ₹49,784.97 Cr | ₹58,502.15 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
† Computed, not printed: that year’s report leaves this figure out, but the lines it does print fix it exactly (hover for the sum). The same relationship holds in every year where all of its lines are printed.
All years: consolidated statements.
10 · Cash Flow Statement — as filed
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| ₹2,562.80 Cr | ₹-1,164.35 Cr | ₹223.41 Cr | ₹-1,021.01 Cr | ₹2,168.60 Cr | |
| ₹3,329.05 Cr | ₹5,016.48 Cr | ₹2,386.75 Cr | ₹2,434.52 Cr | ₹3,924.62 Cr | |
| ₹598.69 Cr | ₹-3,211.56 Cr | ₹-3,977.75 Cr | ₹-4,255.95 Cr | ₹-1,875.80 Cr | |
| ₹-1,364.94 Cr | ₹-2,969.27 Cr | ₹1,814.41 Cr | ₹800.42 Cr | ₹119.78 Cr | |
Cash and cash equivalents at the beginning of the year | ₹2,746.82 Cr | ₹5,329.91 Cr | ₹4,162.51 Cr | ₹4,392.27 Cr | ₹3,385.43 Cr |
Add: Cash and cash equivalents on acquisition of subsidiaries (refer note 38) | ₹22.41 Cr | ₹-3.25 Cr | ₹6.41 Cr | — | ₹66.00 L |
Effect of exchange differences on cash and cash equivalents | ₹-2.12 Cr | ₹20.00 L | ₹-6.00 L | ₹14.17 Cr | ₹9.10 Cr |
Cash and cash equivalents at the end of the year | ₹5,329.91 Cr | ₹4,162.51 Cr | ₹4,392.27 Cr | ₹3,385.43 Cr | ₹5,563.79 Cr |
The company’s own captions, order and figures from its annual reports. A dash means the company printed no figure on that line that year. Each year is read from the latest annual report that carries it and was checked against the headline total shown elsewhere on this page.
All years: consolidated statements.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Mar 24(11Q) | Jun 24 | Sep 24–Mar 26(7Q) | Jun 26 |
|---|---|---|---|---|
| Promoter | 51.83% | 51.80% | 51.82% | 51.88% |
| Public | 48.17% | 48.20% | 48.18% | 48.12% |
| Employee trusts | 0.00% | 0.00% | 0.00% | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.25 L Cr | ₹1,769.9 | 38.8 | 5.09 | 13.7% | 0.06 | +11.9% | +3.7% |
| Divi's Laboratories Limited | ₹2.66 L Cr | ₹10,037.5 | 90.8 | 15.85 | 15.3% | 0.00 | +12.3% | +47.5% |
| Torrent Pharmaceuticals Limited | ₹1.79 L Cr | ₹4,738.5 | 79.4 | 21.31 | 25.8% | 1.79 | +21.5% | +32.5% |
| Laurus Labs Limited | ₹1.27 L Cr | ₹2,348 | 94.8 | 23.94 | 16.8% | 0.48 | +22.0% | +146.2% |
| Apollo Hospitals Enterprise Limited | ₹1.23 L Cr | ₹8,599.5 | 58.8 | 12.95 | 20.5% | 0.90 | +15.7% | +10.1% |
| Zydus Lifesciences Limited | ₹1.19 L Cr | ₹1,188.1 | 26.7 | 4.40 | 18.6% | 0.46 | +18.4% | +22.3% |
| Lenskart Solutions Limited | ₹1.16 L Cr | ₹689.7 | 181.4 | 13.30 | 5.6% | 0.35 | +35.4% | — |
| Dr. Reddy's Laboratories Limited | ₹1.14 L Cr | ₹1,374 | 40.6 | 3.02 | 11.4% | 0.21 | +3.2% | +14.5% |
| Cipla Limited | ₹1.13 L Cr | ₹1,402 | 38.9 | 3.27 | 11.3% | 0.02 | +2.1% | -6.7% |
| Mankind Pharma Limited | ₹1.03 L Cr | ₹2,475 | 45.9 | 6.31 | 11.7% | 0.39 | +17.0% | +3.1% |
| Aurobindo Pharma Limited | ₹98,101.93 Cr | ₹1,705 | 26.6 | 2.59 | 9.2% | 0.21 | +6.4% | +48.4% |
| Lupin Limited | ₹92,244.53 Cr | ₹2,008.6 | 16.7 | 4.11 | 23.8% | 0.29 | +23.9% | +0.6% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Aurobindo Pharma stock: Q2 profit rises 32.5% on record revenue
ad-hoc-news.de · 10 days ago